<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253408</url>
  </required_header>
  <id_info>
    <org_study_id>08-008314 Part A</org_study_id>
    <secondary_id>R01DK079866</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01253408</nct_id>
  </id_info>
  <brief_title>Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)</brief_title>
  <official_title>Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no
      effective and safe medications approved for the treatment of abdominal pain associated with
      bowel symptoms in IBS. This study will investigate the effects of an approved medication,
      Dronabinol, on the movement of food through the stomach and colon in subjects with a history
      of diarrhea-predominant Irritable Bowel Syndrome (D-IBS).

      Dronabinol is a synthetic medication (a medication made in a laboratory) related to the
      active ingredient of &quot;cannabinoid or marijuana&quot;. Dronabinol is approved by the Food and Drug
      Administration (FDA) for preventing nausea and vomiting in patients with cancers undergoing
      chemotherapy. It is also used in AIDS patients with excessive weight loss for improvement in
      appetite and weight gain.

      The hypothesis in this study is that dronabinol will slow down the movement of food through
      the colon, and that this effect is regulated by the genes controlling the body messengers
      (receptors) that respond to medicinal marijuana or synthetic medicines that work on the same
      messengers that are present in the gastrointestinal tract and pain nerves.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. Despite increasing
      understanding of the pathophysiology of IBS, there are unmet clinical needs and no effective
      medication approved for the treatment of abdominal pain associated with IBS. Cannabinoid
      receptors (CBR) are on cholinergic neurons in the brain stem, stomach and colon. A
      cannabinoid receptor type 1 (CB1) antagonist, rimonabant, is effective in induction of weight
      loss; however, the mechanism of this benefit is unclear. Human studies from this lab show
      that a CBR agonist, dronabinol, inhibits gastric and colonic motility, which may alter
      appetite or satiation in obesity, and may have potential in the treatment of IBS. The overall
      focus of the study is on the mechanisms involved in the modulation of gastric and colonic
      motor and sensory functions by cannabinoid receptors (CBR) in health and in IBS. CB1
      receptors are also involved in nociception and in mediating inflammation which are
      increasingly recognized as being potential pathophysiological mechanisms in IBS. The aims of
      the study are to compare the effects of two doses of the cannabinoid agonist, dronabinol (5
      and 10 mg/day) and placebo on gastrointestinal and colonic motor and sensory functions in
      IBS. Also, to determine whether variations in the fatty acid amide hydrolase (FAAH) gene and
      the monoacylglycerol lipase (MGLL) gene (for the rate limiting enzyme, monoacylglycerol
      lipase, for another endocannabinoid, 2-arachidonyl glycerol) influence the pharmacological
      effect of cannabinoid modulation on gastrointestinal motor and sensory functions.

      All participants underwent the following procedures:

        1. Documentation of eligibility, screening questionnaires, and physical examination within
           the month prior to the study. The physical exam included standard rectal and pelvic
           floor examinations to exclude rectal evacuation disorder. This was necessary to ensure
           the diarrhea ws not secondary to &quot;retention of stool with overflow.&quot;

        2. Baseline colonic transit measurement (Geometric Center 24-h and 48-h), off treatment.

        3. Treatment days corresponded to the scintigraphic transit testing days (days 1 and 2)
           with participants receiving the medication to which they were randomized. Scintigraphic
           measurements of gastric, small bowel, and colonic transit were conducted, using a
           previously validated method on days 1 and 2, and were completed with a fasting 48-h scan
           on day 3 when no medication was administered.

           On days 1 and 2, the morning dose of medication was ingested in the research laboratory,
           with the participant fasting. On day 1, the morning dose of medication was administered
           together with the delayed release capsule containing an isotope labeled activated
           charcoal used to measure colonic transit. On day 2, the morning dose of medication was
           given after the 24-h scan. The evening doses on days 1 and 2 were ingested by
           participants at bed time in their homes.

        4. With appropriate consent, a venous blood sample was to be obtained from all participants
           for DNA extraction and pharmacogenomic studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Transit Geometric Center at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit Geometric Center</measure>
    <time_frame>28, 32, and 48 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying Half-Time (t1/2)</measure>
    <time_frame>Approximately 2 hours after radiolabel meal is ingested</time_frame>
    <description>The time for half of the ingested solids or liquids to leave the stomach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling at 6 Hours</measure>
    <time_frame>6 hours after radiolabeled meal was ingested</time_frame>
    <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending Colon Emptying T 1/2</measure>
    <time_frame>48 hours after radiolabeled meal was ingested</time_frame>
    <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying at 2 and 4 Hours</measure>
    <time_frame>2, 4 hours</time_frame>
    <description>Proportion of stomach contents emptied at a 2 and 4 hours.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Dronabinol 2.5 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol 5 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken orally with water twice per day for two days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.</description>
    <arm_group_label>Dronabinol 2.5 mg bid</arm_group_label>
    <arm_group_label>Dronabinol 5 mg bid</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will match study drug; taken orally with water twice per day for two days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Positive for IBS symptoms by Rome III criteria

          -  No prior abdominal surgery (except appendectomy or cholecystectomy)

          -  Baseline Geometric Center at 24 hours is greater/equal to 2.0

          -  Baseline Geometric Center at 48 hours is greater/equal to 3.9

        Exclusion Criteria:

          -  Patients with significant depression (score of greater than 10 on Hospital and Anxiety
             Inventory)

          -  Patients with anxiety (score of greater than 10 on Hospital and Anxiety Inventory)
             will not be allowed to participate. However, patients on stable doses of selective
             serotonin re-uptake inhibitors (SSRIs) or low dose of tricyclic antidepressants will
             be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1638-47.e1-7. doi: 10.1053/j.gastro.2011.07.036. Epub 2011 Jul 29.</citation>
    <PMID>21803011</PMID>
  </reference>
  <results_reference>
    <citation>Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D, Zinsmeister AR. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012 Apr;24(4):358-e169. doi: 10.1111/j.1365-2982.2011.01874.x. Epub 2012 Jan 30.</citation>
    <PMID>22288893</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>February 4, 2013</results_first_submitted>
  <results_first_submitted_qc>March 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2013</results_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr. Michael Camilleri</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>anandamide</keyword>
  <keyword>cannabinoid</keyword>
  <keyword>fatty acid amide hydrolase</keyword>
  <keyword>gastric</keyword>
  <keyword>motility</keyword>
  <keyword>small bowel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Cannabinoid Receptor Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were recruited from a database of patients with irritable bowel syndrome (IBS) who reside within 150 miles of Rochester, Minnesota from October 2008 through April 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dronabinol 2.5 mg Bid</title>
          <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="P2">
          <title>Dronabinol 5 mg Bid</title>
          <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo will be taken orally with water twice per day for two days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dronabinol 2.5 mg Bid</title>
          <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="B2">
          <title>Dronabinol 5 mg Bid</title>
          <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.68" spread="25.08"/>
                    <measurement group_id="B2" value="42.28" spread="16.36"/>
                    <measurement group_id="B3" value="36.7" spread="11.02"/>
                    <measurement group_id="B4" value="41.77" spread="17.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="1.5"/>
                    <measurement group_id="B2" value="31.6" spread="3.9"/>
                    <measurement group_id="B3" value="30.8" spread="1.8"/>
                    <measurement group_id="B4" value="30.50" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit Geometric Center</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>28, 32, and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit Geometric Center</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="1.28"/>
                    <measurement group_id="O2" value="3.60" spread="1.04"/>
                    <measurement group_id="O3" value="3.24" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="1.11"/>
                    <measurement group_id="O2" value="4.05" spread="0.90"/>
                    <measurement group_id="O3" value="3.54" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="0.94"/>
                    <measurement group_id="O2" value="4.60" spread="0.65"/>
                    <measurement group_id="O3" value="4.02" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying Half-Time (t1/2)</title>
        <description>The time for half of the ingested solids or liquids to leave the stomach.</description>
        <time_frame>Approximately 2 hours after radiolabel meal is ingested</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying Half-Time (t1/2)</title>
          <description>The time for half of the ingested solids or liquids to leave the stomach.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.3" spread="33.53"/>
                    <measurement group_id="O2" value="130.7" spread="42.13"/>
                    <measurement group_id="O3" value="138.2" spread="45.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling at 6 Hours</title>
        <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
        <time_frame>6 hours after radiolabeled meal was ingested</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling at 6 Hours</title>
          <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
          <units>percentage of meal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.60" spread="33.76"/>
                    <measurement group_id="O2" value="51.62" spread="29.89"/>
                    <measurement group_id="O3" value="57.46" spread="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascending Colon Emptying T 1/2</title>
        <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
        <time_frame>48 hours after radiolabeled meal was ingested</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ascending Colon Emptying T 1/2</title>
          <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.50" spread="4.62"/>
                    <measurement group_id="O2" value="9.90" spread="5.44"/>
                    <measurement group_id="O3" value="14.53" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying at 2 and 4 Hours</title>
        <description>Proportion of stomach contents emptied at a 2 and 4 hours.</description>
        <time_frame>2, 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying at 2 and 4 Hours</title>
          <description>Proportion of stomach contents emptied at a 2 and 4 hours.</description>
          <units>proportion of stomach contents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.15"/>
                    <measurement group_id="O2" value="0.49" spread="0.17"/>
                    <measurement group_id="O3" value="0.45" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.09"/>
                    <measurement group_id="O2" value="0.90" spread="0.13"/>
                    <measurement group_id="O3" value="0.88" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Colonic Transit Geometric Center at 24 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol 2.5 mg Bid</title>
            <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O2">
            <title>Dronabinol 5 mg Bid</title>
            <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo will be taken orally with water twice per day for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit Geometric Center at 24 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="1.29"/>
                    <measurement group_id="O2" value="3.05" spread="1.02"/>
                    <measurement group_id="O3" value="2.77" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dronabinol 2.5 mg Bid</title>
          <description>Dronabinol 2.5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="E2">
          <title>Dronabinol 5 mg Bid</title>
          <description>Dronabinol 5 mg will be taken orally with water twice per day for two days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo will be taken orally with water twice per day for two days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Drowsiness/tiredness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>&quot;Loopy,&quot; foggy thinking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study included assessment of only four doses of dronabinol over 2 days.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Camilleri</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2306</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

